NeuroOne Medical Technologies Corporation (NMTC) reported preliminary, unaudited fiscal fourth-quarter 2026 product revenue of approximately $3.8 million, up 38.4% from approximately $2.7 million a year earlier. The quarter and fiscal year ended September 30, 2026.
The company also secured a record $4.5 million product purchase order in September and said it expects to release complete fourth-quarter and full-year financial results in December alongside its Form 10-K filing.
- Preliminary fiscal 2026 revenue was approximately $10.5 million, up 15.6% year over year and at the top of its $9.2 million to $10.5 million guidance range.
- Approximately $1.0 million of the record purchase order shipped in September 2026.
- Remaining order shipments of $3.6 million are expected to begin in the first quarter of fiscal 2027 and continue into the second quarter, subject to manufacturing and delivery schedules.
- Open purchase orders for shipments through the first quarter of fiscal 2027 totaled $5.4 million as of September 30, 2026.
- Product orders increased 24.2% in fiscal 2026 compared with fiscal 2025.
$NMTC Insider Trading Activity
$NMTC insiders have traded $NMTC stock on the open market 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $NMTC stock by insiders over the last 6 months:
- DAVID J. WAMBEKE (Chief Business Officer) purchased 33,333 shares for an estimated $66,999
- MARK CHRISTIANSON (Market Development Director) sold 10,000 shares for an estimated $31,772
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$NMTC Hedge Fund Activity
We have seen 7 institutional investors add shares of $NMTC stock to their portfolio, and 25 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLEICHROEDER LP removed 3,333,334 shares (-83.3%) from their portfolio in Q2 2026, for an estimated $10,133,335
- SIO CAPITAL MANAGEMENT, LLC removed 413,847 shares (-83.3%) from their portfolio in Q2 2026, for an estimated $1,258,094
- ESSEX INVESTMENT MANAGEMENT CO LLC removed 218,375 shares (-83.4%) from their portfolio in Q2 2026, for an estimated $663,860
- NORTHERN TRUST CORP removed 90,725 shares (-80.9%) from their portfolio in Q2 2026, for an estimated $275,804
- BLAIR WILLIAM & CO/IL removed 48,056 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $146,090
- XTX TOPCO LTD removed 43,283 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $131,580
- RENAISSANCE TECHNOLOGIES LLC removed 38,380 shares (-35.1%) from their portfolio in Q2 2026, for an estimated $116,675
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
